CAR-T cell therapy
CAR-T 细胞治疗
Treats: Relapsed/refractory B-cell lymphomas, leukemia, multiple myeloma (product-dependent)
At a glance
Approved products (China)
6
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
Source(s)
- 行业盘点(xueqiu 等)
Secondary source (media / community / commercial)
Anchor price (China)
¥1,200,000 per infusion (axi-cel ); relma-cel ¥1,290,000
What this meansChecked against a primary or official source.
Source(s)
- 163.com
Secondary source (media / community / commercial) - xueqiu.com
Secondary source (media / community / commercial)
Last checked2026-09-08
How China compares internationally
International comparison
US CAR-T list prices ≈ USD 400-500k → China ≈ 1/2.4 at list
What this meansReported information that has not yet been independently confirmed.
SourceNo independent source on file.
NotesReported comparison, not independently verified.
Eligibility depends on diagnosis, disease status, prior treatment, and clinical assessment. This page is general information, not medical advice.
Related drugs
Sources & verification
- 行业盘点(xueqiu 等) — Secondary source (media / community / commercial)
- 163.com — Secondary source (media / community / commercial)
- xueqiu.com — Secondary source (media / community / commercial)
Reader discussion
Public comments about CAR-T cell therapy. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.